Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 9/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 8/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293442 | 0.83 | MAP3K7 (0.38) | LATS1LATS2DYRK1ANFATC1GSK3B | |
| SCHEMBL28018750 | 0.76 | ALDH1A1 (0.38) | DYRK1ANFATC1GSK3BHTTCYP2A6 | |
| SCHEMBL8502975 | 0.76 | ALOX5 (0.49) | TSHRCYP2A6KCNH2 | |
| SCHEMBL21173653 | 0.74 | MAP3K7 (0.35) | MAP3K7TAB1 | |
| SCHEMBL20824821 | 0.73 | CYP2A6 (0.37) | GSK3BHTTCYP2A6MAP3K7TAB1 | |
| SCHEMBL12820361 | 0.71 | GRM4 (0.37) | LATS1LATS2DYRK1ANFATC1GSK3B | |
| SCHEMBL3931535 | 0.70 | CYP2A6 (0.41) | HTTCYP2A6MAP3K7TAB1 | |
| SCHEMBL19431248 | 0.69 | CYP2A6 (0.47) | DYRK1ANFATC1GSK3BCYP2A6MAP3K7 | |
| SCHEMBL12877263 | 0.69 | LMNA (0.47) | HTTTSHRMEN1KMT2A | |
| SCHEMBL23095503 | 0.69 | LMNA (0.47) | HTTTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | LATS1 3445/4885LATS2 3131/4885DYRK1A 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.